ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,07125
0,03%
Bitcoin
62.012,28
0,34%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) News

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DatumZeitQuelleÜberschriftSymbolFirma
18/06/202423h14Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SMMTSummit Therapeutics Inc
17/06/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/06/202420h03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SMMTSummit Therapeutics Inc
03/06/202412h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
03/06/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
03/06/202411h30Business WireSummit Raises $200 Million; Also Expands License Territories for IvonescimabNASDAQ:SMMTSummit Therapeutics Inc
01/06/202414h00Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
01/06/202401h00Business Wire Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyNASDAQ:SMMTSummit Therapeutics Inc
31/05/202400h00Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
30/05/202422h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
30/05/202420h29Business WireIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaNASDAQ:SMMTSummit Therapeutics Inc
24/05/202414h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/05/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/05/202413h48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SMMTSummit Therapeutics Inc
01/05/202413h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024NASDAQ:SMMTSummit Therapeutics Inc
24/04/202422h30Business WireSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024NASDAQ:SMMTSummit Therapeutics Inc
11/04/202422h30Business WireSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
10/04/202413h00Business WireSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumNASDAQ:SMMTSummit Therapeutics Inc
22/03/202412h00Business WirePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
14/03/202412h00Business WireIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
05/03/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
05/03/202413h00Business WireSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/02/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h55Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SMMTSummit Therapeutics Inc
20/02/202413h00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
15/02/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
14/02/202422h35Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
14/02/202416h29Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024NASDAQ:SMMTSummit Therapeutics Inc
14/02/202413h00Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AMZN
Amazon.com
DBI
DAX
DAX
TG
TUI1
Tui
TG
432
Arbor Metals
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
LHA
Deutsche Lufthansa
AMEX
SPY
SPDR S&P 500
USOTC
ADDYY
Adidas (QX)
DBI
TDXP
Tec DAX
PM
XAUUSD
Gold vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
TSLA
Tesla
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten